Common mental disorders in Gestalt therapy treatment: a multiple case study comparing patients with moderate and low integrated personality structures

被引:0
|
作者
Kaisler, Raphaela E. [1 ,2 ]
Fede, Manfred [1 ]
Diltsch, Ulla [3 ]
Probst, Thomas [4 ]
Schaffler, Yvonne [1 ]
机构
[1] Univ Continuing Educ Krems, Dept Psychosomat Med & Psychotherapy, Krems, Austria
[2] Bertha von Suttner Private Univ St Polten, Dept Psychotherapy, St Polten, Austria
[3] Osterreich Arbeitskreis Gruppentherapie & Gruppend, Integrat Gestalttherapie, Vienna, Austria
[4] Paris Lodron Univ Salzburg, Dept Psychol, Div Psychotherapy, Salzburg, Austria
来源
FRONTIERS IN PSYCHOLOGY | 2023年 / 14卷
关键词
Gestalt therapy; common mental health disorders; operationalized psychodynamic diagnostic; mixed-methods case study; outcome; process; psychotherapy; EMPOWERMENT SCALE; HEALTH; PSYCHOTHERAPY; RECOVERY; EMOTION; RELIABILITY; CONSUMERS; SEVERITY; VALIDITY; ILLNESS;
D O I
10.3389/fpsyg.2023.1304726
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
IntroductionEmpowerment is central to self-development and growth in Gestalt therapy. The self evolves through interactions with others, forming self- and object-relations, and ego-functions. Underlying structural functions build the ability to regulate, differentiate, and integrate experiences, leading to self-, and emotion-regulation. Our study examined the self-development of seven clients with prevalent mental health issues and structural challenges, all of whom underwent 30 sessions of Gestalt therapy in a real-world individual therapy context.MethodsUsing a multiple case study approach, we contrasted two client groups: those with moderately integrated and those with low-integrated personality structures, as defined by the operationalised psychodynamic diagnostic manual. Our exploration centered on specific factors of empowerment, therapy processes, and interventions. The study's mixed-method design encompassed quantitative outcome measures (empowerment, wellbeing, psychosocial health, and severity of personality functioning), therapy diaries from both clients and therapists, and semi-structured client interviews about empowering factors in therapy.ResultsBoth groups showed positive therapy outcomes on wellbeing, psychosocial health, and empowerment. Specific empowerment-related factors included promoting experiences, relationships, and self-efficacy in the low-integrated group. Support of self-regulation was reported to be essential for successful outcomes in the moderately integrated group. While the therapy processes proceeded similarly in both groups, we observed a strong focus on body awareness-oriented interventions and promotion of verbalisation in the low-integrated group and a relationship-oriented emphasis in the moderately integrated group. Emotional experience linked to positive experience was limited in the low-integrated group, suggesting an impairment of emotional processing, including bodily felt feelings. No change was reported in the level of personality functioning after 30 sessions in both groups.DiscussionThese results underscore the need for tailored therapeutic approaches based on the client's level of personality integration. Future research should probe the long-term effects of therapy and delve deeper into shifts in personality functioning, especially concerning emotional and bodily experiences. In practical terms, therapists should prioritize linking bodily sensations with emotions for clients with low-integrated personalities. For those with moderate integration, the emphasis should be on fostering exploration, awareness, and bolstering self-regulation.
引用
收藏
页数:20
相关论文
共 47 条
  • [41] Treatment-naive patients with early-stage relapsingremitting multiple sclerosis showed low disease activity after 2-year ocrelizumab therapy, with no new safety signals; the Phase IIIb ENSEMBLE study
    Hartung, H. -P.
    Brochet, B.
    Freedman, M.
    Vollmer, T.
    Holmoy, T.
    Karabudak, R.
    Nos, C.
    Vanopdenbosch, L.
    Kuenzel, T.
    Kadner, K.
    Kulyk, I.
    Killestein, J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 325 - 326
  • [42] Low disability accumulation after 4-year ocrelizumab therapy in treatment-naive patients with early-stage relapsing-remitting multiple sclerosis; data from the Phase IIIb ENSEMBLE study
    Patti, Francesco
    Bermel, Robert
    Brochet, Bruno
    Berger, Thomas
    Carroll, William
    Freedman, Mark S.
    Holmoy, Trygve
    Karabudak, Rana
    Killestein, Joep
    Nos, Carlos
    Vanopdenbosch, Ludo
    Vollmer, Timothy
    Kuenzel, Thomas
    Kadner, Karen
    Kulyk, Inessa
    Hartung, Hans-Peter
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 594 - 596
  • [43] A phase I study of lenalidomide with pioglitazone, dexamethasone and low-dose treosulfan: Combined anti-inflammatory, immunomodulatory and angiostatic treatment as third-line therapy for patients (pts) suffering from multiple myeloma (MM)
    Reichle, A.
    Vogelhuber, M.
    Kreuser, E. -D.
    Wilke, J.
    Wagner, H.
    Straka, C.
    Pronath, A.
    Andreesen, R.
    ONKOLOGIE, 2011, 34 : 160 - 160
  • [44] Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)
    Pellegrino Musto
    Vittorio Simeon
    Nicola Cascavilla
    Antonietta Falcone
    Maria Teresa Petrucci
    Laura Cesini
    Francesco Di Raimondo
    Concetta Conticello
    Roberto Ria
    Lucio Catalano
    Dalila Salvatore
    Lucia Mastrullo
    Alfredo Gagliardi
    Oreste Villani
    Giuseppe Pietrantuono
    Giovanni D’Arena
    Giovanna Mansueto
    Sara Bringhen
    Mariella Genuardi
    Nicola Di Renzo
    Giovanni Reddiconto
    Alberto Fragasso
    Tommaso Caravita
    Daniele Scapicchio
    Gioacchino Marziano
    Mario Boccadoro
    Silvia Mangiacavalli
    Alessandro Corso
    Annals of Hematology, 2019, 98 : 361 - 367
  • [45] Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)
    Musto, Pellegrino
    Simeon, Vittorio
    Cascavilla, Nicola
    Falcone, Antonietta
    Petrucci, Maria Teresa
    Cesini, Laura
    Di Raimondo, Francesco
    Conticello, Concetta
    Ria, Roberto
    Catalano, Lucio
    Salvatore, Dalila
    Mastrullo, Lucia
    Gagliardi, Alfredo
    Villani, Oreste
    Pietrantuono, Giuseppe
    D'Arena, Giovanni
    Mansueto, Giovanna
    Bringhen, Sara
    Genuardi, Mariella
    Di Renzo, Nicola
    Reddiconto, Giovanni
    Fragasso, Alberto
    Caravita, Tommaso
    Scapicchio, Daniele
    Marziano, Gioacchino
    Boccadoro, Mario
    Mangiacavalli, Silvia
    Corso, Alessandro
    ANNALS OF HEMATOLOGY, 2019, 98 (02) : 361 - 367
  • [46] A novel approach to treatment of hypertension in diabetic patients – a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 – rationale and design [ISRCTN55725285]
    Cornel Pater
    Deepak Bhatnagar
    Jean-Pascal Berrou
    Joachim Luszick
    Katrin Beckmann
    Current Controlled Trials in Cardiovascular Medicine, 2004, 5
  • [47] A novel approach to treatment of hypertension in diabetic patients - a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design [ISRCTN55725285]
    Pater, C
    Bhatnagar, D
    Berrou, JP
    Luszick, J
    Beckmann, K
    CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE, 2004, 5 (1):